May 31st 2024
The FDA has granted a fast track designation to AGuIX, a gadolinium-based nanodrug currently under evaluation for treating malignant gliomas and glioblastoma.
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Metabolic Pathways May Provide Opportunity for Novel Therapeutic Targeting in Neuro-Oncology
December 21st 2016In an interview with <em>Targeted Oncology</em>, Howard Fine discusses the reason for renewed interested in metabolic targets, the effect it has had on treatment of gliomas, and what he sees on the horizon for neuro-oncology in this area.<br />
Read More
No Clinical Benefit From Added Onartuzumab Demonstrated in Glioblastoma Study
December 21st 2016Treatment with onartuzumab did not provide any additional clinical benefit when added to bevacizumab (Avastin) in the treatment of patients with recurrent glioblastoma multiforme (GBM), according to a study recently published in the <em>Journal of Clinical Oncology</em>.
Read More
Entrectinib Will Likely Play an Increasing Role in Treating Brain Tumors, Other Cancers, Expert Says
November 30th 2016Researchers are currently investigating the use of tropomyosin receptor kinase (TRK) inhibitor entrectinib (RXDX-101) to treat patients with relapsed or refractory solid tumors or primary tumors of the central nervous system.
Read More
Study Findings Show Role for Pembrolizumab and Durvalumab in GBM Treatment, Expert Says
November 21st 2016Based on encouraging efficacy signals and safety data from separate trials exploring the PD-1 inhibitor pembrolizumab (Keytruda) and the PD-L1 inhibitor durvalumab (MEDI4736), there is a role for checkpoint inhibitors in the treatment of glioblastoma multiforme (GBM).
Read More
Proposed Phase II Trial Aims to Explore Optune System in Grade III Recurrent Glioma
November 21st 2016Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields device.
Read More
Nivolumab Combinations Feasible for Newly Diagnosed GBM
November 20th 2016The PD-1 inhibitor nivolumab was successfully combined with radiotherapy alone or concurrently with temozolomide for patients with newly-diagnosed glioblastoma multiforme in cohorts 1c and 1d from the phase I CheckMate-143 study.
Read More
Novel Gene Therapy Effective for High-Grade Gliomas
November 19th 2016Treatment with the novel regimen of Toca 511 and Toca FC demonstrated a median overall survival of 13.6 months for patients with high-grade gliomas, representing a marked improvement over historical median survivals of 7.2 to 9.2 months.<br />
Read More
CVS Cuts Out In-House Dispensaries of Cancer Drugs
October 20th 2016A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs, the Community Oncology Alliance (COA) argued in a new white paper.
Read More
What's Next for Immunotherapy in GBM: IDO Inhibitors, Vaccines, and PD-L1 Antibody Combinations
October 18th 2016Rimas Lukas, MD, discusses the next steps in glioblastoma research, as well as the potential use of IDO inhibitors in the treatment of GBM, and recent studies showing promise in the field.
Read More
Tumor-Treating Fields Make Significant Impact in GBM and Beyond
October 18th 2016Optune, a noninvasive device that delivers tumor-treating fields to the brain, provides oncologists, specifically those who treat glioblastoma multiforme, an opportunity to apply technology as part of their standard treatment regimen.
Read More
Computer Simulation Helps Plan Transducer Placement in Glioblastoma
October 14th 2016For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields (TTF) and employing a personalized transducer array, delivered electric field (EF) intensities that exceeded therapeutic intensities in 3 different tumor locations.
Read More
The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade Gliomas
October 9th 2016Mark Kieran, MD, PhD, director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, discusses the results of a study that evaluated dabrafenib as a treatment for pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas during an interview at the 2016 ESMO Congress.
Watch
Researchers Join Forces to Accelerate Progress in Pediatric High-Grade Gliomas
September 20th 2016Goals of "Project Impact: A Campaign to Defeat Pediatric Brain Tumors" include improving clinical outcomes for pediatric brain tumor patients and informing the development of the first-ever standard of care for treating pediatric high-grade gliomas.
Read More